Imricor Medical Systems (ASX:IMR) said that its Advantage-MR electrophysiology recording and cardiac stimulator system received CE mark certification under the European Union's new medical device regulations regime, according to a Thursday Australian bourse filing.
The commercial launch of its second-generation Vision-MR ablation catheter and the new Advantage-MR system is planned to start in June across new and existing sites in the EU.
In February, the company's second-generation Vision-MR ablation catheter received CE mark approval under the medical device regulations regime.
Imricor's shares fell almost 4% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。